Shattuck Labs (STTK) filed a shelf registration statement with US regulators on late Tuesday for the potential sale of up to $200 million in securities, to be offered from time to time.
The filing covers common stock, preferred stock, debt securities, warrants and units.
The company said the offering proceeds will fund clinical trials, product development, general corporate needs, and potential acquisitions, with unused funds held in safe investments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.